Form 4: Indaptus Therapeutics Director Acquires Stock Options

Mark John Gilbert, a director of Indaptus Therapeutics, acquired stock options exercisable for 12,500 shares of common stock.

Summary

• On June 6, 2024, Mark John Gilbert, a director of Indaptus Therapeutics, Inc., acquired stock options.
• The options grant the right to buy 12,500 shares of common stock at an exercise price of $2.63 per share.
• The stock options vest and become exercisable on June 6, 2025.
• The options expire on June 6, 2034.
• Following the transaction, Gilbert directly owns 12,500 derivative securities.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It's common for directors and officers of publicly traded companies to receive stock options as part of their compensation.

Key Dates

Keywords

stock options, Indaptus Therapeutics, director, Mark John Gilbert, beneficial ownership, Form 4